Arcutis Biotherapeutics vs Innoviva
Innoviva reported revenue of $411 million in fiscal 2025, about the same as Arcutis Biotherapeutics' $376 million in fiscal 2025. Arcutis Biotherapeutics' revenue grew 91.3% in its latest year, and Innoviva's grew 14.7%. Arcutis Biotherapeutics had an operating margin of -3.2%, against 39.8% at Innoviva. Free cash flow was −$6 million at Arcutis Biotherapeutics and $196 million at Innoviva.
Side by side
| Arcutis Biotherapeutics | Innoviva | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $376M | $411M |
| Revenue growth | 91.3% | 14.7% |
| Revenue growth a year, last 5 years | — | 4.1% |
| Gross margin | 90.2% | 74.8% |
| Operating margin | −3.2% | 39.8% |
| Net margin | −4.3% | 65.9% |
| Free cash flow | −$6M | $196M |
| Free cash flow margin | −1.7% | 47.6% |
| Return on capital | −16.9% | 17.9% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $4M |
| Change in diluted share count | 5.2% | 14.2% |
| Last close | $28.26 | $19.03 |
| P/E at the last close | 134.6× | 9.5× |
| Insider trades, last 12 months | sold $12.2 million | — |
| Piotroski F-score | 4 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arcutis BiotherapeuticsInnoviva
Operating margin
Percent of revenue
Arcutis BiotherapeuticsInnoviva
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcutis BiotherapeuticsInnoviva
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcutis Biotherapeutics and Innoviva pages.